Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on the Effectiveness and Safety of Betaine Citrate for Treating Functional Dyspepsia in Adults

Registered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the condition known as Functional Dyspepsia, which is a type of indigestion that causes discomfort or pain in the upper abdomen. The trial will evaluate the effectiveness and safety of a treatment called ALKACITRAT, which contains the active substance Betaine Citrate. Participants in the study will receive either the ALKACITRAT treatment or a placebo, which looks like the treatment but does not contain the active substance.

The purpose of the study is to assess how well ALKACITRAT works in relieving symptoms of functional dyspepsia and to ensure it is safe for use. Participants will take the treatment orally, meaning it is swallowed, over a period of time. Throughout the study, researchers will monitor the participants to see if there is an improvement in their symptoms and to check for any side effects.

The study will compare the results between those taking ALKACITRAT and those taking the placebo to determine the treatment's effectiveness. Researchers will look at changes in the severity of symptoms and overall quality of life. The study will also track any adverse events, which are unexpected medical problems that may occur during the trial. The findings will help in understanding whether ALKACITRAT is a beneficial treatment option for people with functional dyspepsia.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, eligibility is confirmed based on specific criteria. Participants must be between 18 and 75 years old, meet the Rome IV criteria for functional dyspepsia, and have a GOS score of 4 or higher. Participants must also be legally competent and able to understand the study information, voluntarily agree to participate, and sign the informed consent form.

  2. Step 2

    Baseline visit (V0)

    During the baseline visit, initial assessments are conducted. These assessments include evaluating symptoms and quality of life using specific scales such as the GOS score and NDI-SF index. This visit establishes a reference point for future comparisons.

  3. Step 3

    Treatment phase

    Participants receive the investigational medicinal product, ALKACITRAT, in the form of an oral solution. The dosage is 2 grams per tablet, taken as directed. The treatment aims to evaluate the effectiveness and safety of ALKACITRAT in treating functional dyspepsia.

  4. Step 4

    End of treatment visit (V1)

    At the end of the treatment phase, a follow-up visit is conducted. The primary endpoint is the comparison of the percentage of patients with improvement in symptoms, measured by a change in the GOS score. Secondary endpoints include changes in quality of life, symptom severity, and the frequency and type of any adverse events.

Who can join the trial?

6 criteria

  • Men and women who are between 18 and 75 years old.
  • Patients who have symptoms of **functional dyspepsia**. This is a type of indigestion that doesn't have a clear cause.
  • Patients who meet the **Rome IV criteria** for functional dyspepsia. These are specific guidelines doctors use to diagnose this condition.
  • Patients with a **GOS score** of 4 or higher. This is a way to measure the severity of symptoms.
  • Patients who are legally able to make decisions and understand the study details.
  • Patients who have been informed about the study, understand its purpose, and agree to participate by signing a consent form.

Who cannot join the trial?

9 criteria

  • Patients who are pregnant or breastfeeding cannot participate.
  • Individuals with a history of severe allergies to medications are excluded.
  • People currently participating in another clinical trial are not eligible.
  • Patients with serious heart conditions, such as heart failure, are excluded.
  • Individuals with liver or kidney disease cannot take part.
  • People with a history of alcohol or drug abuse are not eligible.
  • Patients with mental health disorders that are not well-controlled are excluded.
  • Individuals who have had stomach surgery in the past are not eligible.
  • People who are unable to follow the study procedures or instructions cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

ALKACITRAT is being studied for its effectiveness and safety in treating functional dyspepsia. Functional dyspepsia is a common digestive disorder that causes discomfort or pain in the upper abdomen. The trial aims to determine how well ALKACITRAT works in relieving the symptoms associated with this condition and to ensure that it is safe for patients to use.

What is already known about the treatment

ALKACITRAT – This medication is administered orally in the form of tablets. It is currently being evaluated in clinical trials for its effectiveness and safety in treating functional dyspepsia, a common digestive disorder. ALKACITRAT is primarily indicated for relieving symptoms associated with this condition, such as stomach discomfort and bloating. Its mechanism of action involves neutralizing stomach acid, which helps to alleviate irritation in the stomach lining. ALKACITRAT is classified as an antacid in pharmacology.

Investigated diseases

Functional Dyspepsia – Functional dyspepsia is a common digestive disorder characterized by persistent or recurring pain or discomfort in the upper abdomen. It is not caused by any identifiable structural or biochemical abnormalities. Symptoms often include bloating, nausea, and a feeling of fullness after eating only a small amount of food. The condition can be triggered by stress, diet, or other lifestyle factors. It tends to be chronic, with symptoms that can fluctuate in intensity over time. The exact cause of functional dyspepsia is not well understood, but it is believed to involve a combination of factors, including abnormal motility and heightened sensitivity of the stomach.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-512688-30-00Protocol codeUNI-BETAINEstimated enrolment92 patientsSponsorUni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).